Indiana University Center for Neuroimaging, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Drug Alcohol Depend. 2013 Feb 1;128(1-2):52-7. doi: 10.1016/j.drugalcdep.2012.07.016. Epub 2012 Aug 19.
Although the incidence of cannabis abuse/dependence in Americans is rising, the neurobiology of cannabis addiction is not well understood. Imaging studies have demonstrated deficits in striatal D(2)/D(3) receptor availability in several substance-dependent populations. However, this has not been studied in currently using chronic cannabis users.
The purpose of this study was to compare striatal D(2)/D(3) receptor availability between currently using chronic cannabis users and healthy controls.
Eighteen right-handed males age 18-34 were studied. Ten subjects were chronic cannabis users; eight were demographically matched controls. Subjects underwent a [(11)C]raclopride (RAC) PET scan. Striatal RAC binding potential (BP(ND)) was calculated on a voxel-wise basis. Prior to scanning, urine samples were obtained from cannabis users for quantification of urine Δ-9-tetrahydrocannabinol (THC) and THC metabolites (11-nor-Δ-9-THC-9-carboxylic acid; THC-COOH and 11-hydroxy-THC;OH-THC).
There were no differences in D(2)/D(3) receptor availability between cannabis users and controls. Voxel-wise analyses revealed that RAC BP(ND) values were negatively associated with both urine levels of cannabis metabolites and self-report of recent cannabis consumption.
In this sample, current cannabis use was not associated with deficits in striatal D(2)/D(3) receptor availability. There was an inverse relationship between chronic cannabis use and striatal RAC BP(ND). Additional studies are needed to identify the neurochemical consequences of chronic cannabis use on the dopamine system.
尽管美国人滥用/依赖大麻的发病率正在上升,但大麻成瘾的神经生物学机制仍不清楚。影像学研究表明,在几种物质依赖人群中,纹状体 D2/D3 受体的可用性存在缺陷。然而,这在目前正在使用慢性大麻的使用者中尚未得到研究。
本研究旨在比较目前正在使用慢性大麻的使用者和健康对照者纹状体 D2/D3 受体的可用性。
研究了 18 名 18-34 岁的右利手男性。10 名受试者为慢性大麻使用者;8 名是在人口统计学上与之匹配的对照者。受试者接受了 [(11)C]raclopride (RAC) PET 扫描。在体素基础上计算纹状体 RAC 结合潜能 (BP(ND))。在扫描前,从大麻使用者的尿液中获取样本,以定量检测尿液中的 Δ-9-四氢大麻酚 (THC) 和 THC 代谢物(11-去甲-Δ-9-THC-9-羧酸;THC-COOH 和 11-羟基-THC;OH-THC)。
大麻使用者和对照组之间的 D2/D3 受体可用性没有差异。体素分析显示,RAC BP(ND) 值与尿液中大麻代谢物的水平和最近大麻使用的自我报告呈负相关。
在本样本中,目前的大麻使用与纹状体 D2/D3 受体的可用性缺陷无关。慢性大麻使用与纹状体 RAC BP(ND) 呈负相关。需要进一步的研究来确定慢性大麻使用对多巴胺系统的神经化学后果。